Background: It has been generally accepted that being overweight or obese is a risk factor for several types of cancers, including breast, thyroid, colon, pancreatic and liver. In fact, people who are obese have more fat tissues that can produce hormones, such as insulin or estrogen, which may cause cancer cells to grow. Alpha lipoic acid (ALA) is anorganosulfur compound derived from octanoic acid, which is produced in animals normally, and is essential for aerobic metabolism. Summary: Studies in both in vitro cells and in vivo animal models have shown that ALA inhibits the initiation and promotion stages of carcinogenesis, suggesting that ALA has considerable attention as a chemopreventive agent. This brief review collects the scattered data available in the literature concerning ALA and highlights its anti-cancer properties, intermediary metabolism and exploratory implications. Key Messages: Based on scientific evidences so far, ALA might be useful agents in the management or chemoprevention of obesity-related cancers.

Keywords:
Obesity, Alpha lipoic acid, Obesity-related cancers, Anti-cancer property, Metabolism
1.
Katsareli EA, Dedoussis GV: Biomarkers in the field of obesity and its related comorbidities. Expert Opin Ther Targets 2014;18:385-401.
2.
Kucukhuseyin O, Kurnaz O, Akadam-Teker AB, et al: The association of MTHFR C677T gene variants and lipid profiles or body mass index in patients with diabetic and nondiabetic coronary heart disease. J Clin Lab Anal 2013;27:427-434.
3.
Razzaghi H, Troester MA, Gierach GL, et al: Mammographic density and breast cancer risk in white and African American women. Breast Cancer Res Treat 2012;135:571-580.
4.
Abdel-Zaher AO, Abdel-Hady RH, Mahmoud MM, et al: The potential protective role of alpha-lipoic acid against acetaminophen-induced hepatic and renal damage. Toxicology 2008;243:261-270.
5.
Spechler SJ: Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013;310:627-636.
6.
Orecchioni S, Reggiani F, Talarico G, et al: Mechanisms of obesity in the development of breast cancer. Discov Med 2015;20:121-128.
7.
Pellegriti G, Frasca F, Regalbuto C, et al: Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013;2013:965212.
8.
Hemminki K, Li X, Sundquist J, et al: Obesity and familial obesity and risk of cancer. Eur J Cancer Prev 2011;20:438-443.
9.
O'Flanagan CH, Bowers LW, Hursting SD: A weighty problem: metabolic perturbations and the obesity-cancer link. Horm Mol Biol Clin Investig 2015;23:47-57.
10.
Szabo G, Saha B, Bukong TN: Alcohol and HCV: implications for liver cancer. Adv Exp Med Biol 2015;815:197-216.
11.
Mazzarella L: Why does obesity promote cancer? Epidemiology, biology, and open questions. Ecancermedicalscience 2015;9:554.
12.
Matsunaga T, Suzuki K, Imashimizu K, Banno T, Takamochi K, Oh S: Body mass index as a prognostic factor in resected lung cancer: obesity or underweight, which is the risk factor? Thorac Cardiovasc Surg 2015;63:551-557.
13.
Tseng JH, Roche KL, et al: Lifestyle and weight management counseling in uterine cancer survivors: a study of the uterine cancer action network. Int J Gynecol Cancer 2015;25:1285-1291.
14.
Travis LB, Demark Wahnefried W, et al: Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013;10:289-301.
15.
Chen J, Zhao KN, Li R, et al: Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer. Curr Med Chem 2014;21:3070-3080.
16.
Habeeb BS, Kitayama J, Nagawa H: Adiponectin supports cell survival in glucose deprivation through enhancement of autophagic response in colorectal cancer cells. Cancer Sci 2011;102:999-1006.
17.
Kubota Y, Iso H, Tamakoshi A; JACC Study Group: Association of body mass index and mortality in Japanese diabetic men and women based on self-reports: the Japan collaborative cohort (JACC) study. J Epidemiol 2015;25:553-558.
18.
Mignini F, Nasuti C, Fedeli D, et al: Protective effect of alpha-lipoic acid on cypermethrin-induced oxidative stress in Wistar rats. Int J Immunopathol Pharmacol 2013;26:871-881.
19.
Dwivedi N, Flora G, Kushwaha P, et al: Alpha-lipoic acid protects oxidative stress, changes in cholinergic system and tissue histopathology during co-exposure to arsenic-dichlorvos in rats. Environ Toxicol Pharmacol 2014;37:7-23.
20.
Keith DJ, Butler JA, Bemer B, et al: Age and gender dependent bioavailability of R- and R,S-α-lipoic acid: a pilot study. Pharmacol Res 2012;66:199-206.
21.
Yamada T, Hashida K, Takarada-Iemata M, et al: α-Lipoic acid (LA) enantiomers protect SH-SY5Y cells against glutathione depletion. Neurochem Int 2011;59:1003-1009.
22.
Koga T, Ishida T, Takeda T, et al: Restoration of dioxin-induced damage to fetal steroidogenesis and gonadotropin formation by maternal co-treatment with α-lipoic acid. PLoS One 2012;7:e40322.
23.
Shaafi S, Afrooz MR, Hajipour B, et al: Anti-oxidative effect of lipoic acid in spinal cord ischemia/reperfusion. Med Princ Pract 2011;20:19-22.
24.
Valdecantos MP, Pérez-Matute P, Quintero P, et al: Vitamin C, resveratrol and lipoic acid actions on isolated rat liver mitochondria: all antioxidants but different. Redox Rep 2010;15:207-216.
25.
Xia H, Nan Y, Huang X, et al: Effects of tauroursodeoxycholic acid and alpha-lipoic-acid on the visual response properties of cat retinal ganglion cells: an in vitro study. Invest Ophthalmol Vis Sci 2015;56:6638-6645.
26.
Durand M, Mach N: [Alpha lipoic acid and its antioxidant against cancer and diseases of central sensitization]. Nutr Hosp 2013;28:1031-1038.
27.
Moungjaroen J, Nimmannit U, Callery PS, et al: Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation. J Pharmacol Exp Ther 2006;319:1062-1069.
28.
Dozio E, Ruscica M, Passafaro L, et al: The natural antioxidant alpha-lipoic acid induces p27(Kip1)-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells. Eur J Pharmacol 2010;641:29-34.
29.
Trivedi PP, Jena GB: Role of α-lipoic acid in dextran sulfate sodium-induced ulcerative colitis in mice: studies on inflammation, oxidative stress, DNA damage and fibrosis. Food Chem Toxicol 2013;59:339-355.
30.
Omran OM, Omer OH: The effects of alpha-lipoic acid on breast of female albino rats exposed to malathion: histopathological and immunohistochemical study. Pathol Res Pract 2015;211:462-469.
31.
Choi HJ, Kim TY, Ruiz-Llorente S, et al: Alpha-lipoic acid induces sodium iodide symporter expression in TPC-1 thyroid cancer cell line. Nucl Med Biol 2012;39:1275-1280.
32.
Wenzel U, Nickel A, Daniel H: Alpha-lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2-*-generation. Apoptosis 2005;10:359-368.
33.
Berkson BM, Rubin DM, Berkson AJ: Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther 2009;8:416-422.
34.
Ueda K, Asai Y, Yoshimura Y, et al: Effect of oil-in-water lipid emulsions prepared with fish oil or soybean oil on the growth of MCF-7 cells and HepG2 cells. J Pharm Pharmacol 2008;60:1069-1075.
35.
Kumar P, Kadakol A, Shasthrula PK, et al: Curcumin as an adjuvant to breast cancer treatment. Anticancer Agents Med Chem 2015;15:647-656.
36.
Na MH, Seo EY, Kim WK: Effects of alpha-lipoic acid on cell proliferation and apoptosis in MDA-MB-231 human breast cells. Nutr Res Pract 2009;3:265-271.
37.
Dozio E, Ruscica M, Passafaro L, et al: The natural antioxidant alpha-lipoic acid induces p27(Kip1)-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells. Eur J Pharmacol 2010;641:29-34.
38.
Feuerecker B, Pirsig S, Seidl C, et al: Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo. Cancer Biol Ther 2012;13:1425-1435.
39.
Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-899.
40.
Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-1033.
41.
Sugden MC, Holness MJ: Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab 2003;284:E855-E862.
42.
Rossi C, Di Lena A, La Sorda R, et al: Intestinal tumour chemoprevention with the antioxidant lipoic acid stimulates the growth of breast cancer. Eur J Cancer 2008;44:2696-2704.
43.
Li LC, Liu GD, Zhang XJ, et al: Autophagy, a novel target for chemotherapeutic intervention of thyroid cancer. Cancer Chemother Pharmacol 2014;73:439-449.
44.
Rajoria S, Hanly E, Nicolini A, et al: Interlinking of hypoxia and estrogen in thyroid cancer progression. Curr Med Chem 2014;21:1351-1360.
45.
Jeon MJ, Kim WG, Lim S, et al: Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells. Mol Cell Endocrinol 2016;419:113-123.
46.
Ridereau-Zins C: Imaging in colonic cancer. Diagn Interv Imaging 2014;95:475-483.
47.
Sebio A, Kahn M, Lenz HJ: The potential of targeting Wnt/β-catenin in colon cancer. Expert Opin Ther Targets 2014;18:611-615.
48.
Ishii N: Role of oxidative stress from mitochondria on aging and cancer. Cornea 2007;26(9 suppl 1):S3-S9.
49.
Kang J, Chong SJ, Ooi VZ, et al: Overexpression of Bcl-2 induces STAT-3 activation via an increase in mitochondrial superoxide. Oncotarget 2015;6:34191-34205.
50.
Park S, Choi SK, Choi Y, et al: AMPK/p53 axis is essential for α-lipoic acid-regulated metastasis in human and mouse colon cancer cells. J Investig Med 2015;63:882-885.
51.
Yoo TH, Lee JH, Chun HS, et al: Lipoic acid prevents p53 degradation in colon cancer cells by blocking NF-κB induction of RPS6KA4. Anticancer Drugs 2013;24:555-565.
52.
Hiratsuka T, Inomata M, Kono Y, et al: DHL - TauZnNa, a newly synthesized α-lipoic acid derivative, induces autophagy in human colorectal cancer cells. Oncol Rep 2013;29:2140-2146.
53.
Cao Z, Tian R, Zhang T, et al: Localized autoimmune pancreatitis: report of a case clinically mimicking pancreatic cancer and a literature review. Medicine (Baltimore) 2015;94:e1656.
54.
Schmidt-Hansen M, Berendse S, Hamilton W: Symptoms of pancreatic cancer in primary care: a systematic review. Pancreas 2015, Epub ahead of print.
55.
Takai E, Yachida S: Genomic alterations in pancreatic cancer and their relevance to therapy. World J Gastrointest Oncol 2015;7:250-258.
56.
Timofte D, Livadariu R, Bintintan V, et al: Metabolic disorders in patients operated for pancreatic cancer. Rev Med Chir Soc Med Nat Iasi 2014;118:392-398.
57.
Fiore M, de Stefano G, Coppola N, et al: Synchronous and metachronous gastric gist with pancreatic adenocarcinoma: report of 2 cases and a review of literature. Gastroenterol Hepatol Bed Bench 2015;8:298-301.
58.
Kim HS, Kim HJ, Park KG, et al: Alpha-lipoic acid inhibits matrix metalloproteinase-9 expression by inhibiting NF-kappaB transcriptional activity. Exp Mol Med 2007;39:106-113.
59.
Guais A, Baronzio G, Sanders E, et al: Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report. Invest New Drugs 2012;30:200-211.
60.
Berkson BM, Rubin DM, Berkson AJ: Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther 2009;8:416-422.
61.
Wang F, Wang H, Sun X, et al: Apoptosis-induction is a novel therapeutic strategy for gastrointestinal and liver cancers. Curr Gene Ther 2015;15:193-200.
62.
Djenic B, Duick D, Newell JO, et al: Solitary liver metastasis from follicular variant papillary thyroid carcinoma: a case report and literature review. Int J Surg Case Rep 2015;6C:146-149.
63.
Fang C, Fang C, Tian J: [The clinical application of near-infrared light imaging mediated by indocyanine green in liver cancer surgery]. Zhonghua Wai Ke Za Zhi 2015;53:155-157.
64.
Montella M, D'Arena G, Crispo A, et al: Role of sex hormones in the development and progression of hepatitis B virus-associated hepatocellular carcinoma. Int J Endocrinol 2015;2015:854530.
65.
Ringelhan M, Protzer U: Oncogenic potential of hepatitis B virus encoded proteins. Curr Opin Virol 2015;14:109-115.
66.
Oh IS, Park SH: Immune-mediated liver injury in hepatitis B virus infection. Immune Netw 2015;15:191-198.
67.
Shi DY, Liu HL, Stern JS, et al: Alpha-lipoic acid induces apoptosis in hepatoma cells via the PTEN/Akt pathway. FEBS Lett 2008;582:1667-1671.
68.
Fujii Y, Segawa R, Kimura M, et al: Inhibitory effect of α-lipoic acid on thioacetamide-induced tumor promotion through suppression of inflammatory cell responses in a two-stage hepatocarcinogenesis model in rats. Chem Biol Interact 2013;205:108-118.
69.
Simbula G, Columbano A, Ledda-Columbano GM, et al: Increased ROS generation and p53 activation in alpha-lipoic acid-induced apoptosis of hepatoma cells. Apoptosis 2007;12:113-123.
70.
Sudheesh NP, Ajith TA, Janardhanan KK: Hepatoprotective effects of DL-α-lipoic acid and α-tocopherol through amelioration of the mitochondrial oxidative stress in acetaminophen challenged rats. Toxicol Mech Methods 2013;23:368-376.
71.
Perra A, Pibiri M, Sulas P, et al: Alpha-lipoic acid promotes the growth of rat hepatic pre-neoplastic lesions in the choline-deficient model. Carcinogenesis 2008;29:161-168.
72.
Zhang A, Silverberg JI: Association of atopic dermatitis with being overweight and obese: a systematic review and metaanalysis. J Am Acad Dermatol 2015;72:606-616.
73.
Simmonds M, Burch J, Llewellyn A, et al: The use of measures of obesity in childhood for predicting obesity and the development of obesity-related diseases in adulthood: a systematic review and meta-analysis. Health Technol Assess 2015;19:1-336.
74.
Mastrangelo G, Fadda E, Cegolon L: Endotoxin and cancer chemo-prevention. Cancer Epidemiol 2013;37:528-533.
75.
Genova C, Rijavec E, Truini A, et al: Pemetrexed for the treatment of non-small cell lung cancer. Expert Opin Pharmacother 2013;14:1545-1558.
76.
Koufaki M: Therapeutic applications of lipoic acid: a patent review (2011-2014). Expert Opin Ther Pat 2014;24:993-1005.
77.
Marshall AW, Graul RS, Morgan MY, et al: Treatment of alcohol-related liver disease with thioctic acid: a six month randomised double-blind trial. Gut 1982;23:1088-1093.
78.
Kähler W, Kuklinski B, Rühlmann C, et al: [Diabetes mellitus - a free radical-associated disease. Results of adjuvant antioxidant supplementation]. Z Gesamte Inn Med 1993;48:223-232.
79.
McMackin CJ, Widlansky ME, Hamburg NM: Effect of combined treatment with alpha-lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. J Clin Hypertens (Greenwich) 2007;9:249-255.
80.
Jariwalla RJ, Lalezari J, Cenko D, et al: Restoration of blood total glutathione status and lymphocyte function following alpha-lipoic acid supplementation in patients with HIV infection. J Altern Complement Med 2008;14:139-146.
81.
Lott IT, Doran E, Nguyen VQ, et al: Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am J Med Genet A 2011;155A:1939-1948.
82.
Mantovani G, Macciò A, Madeddu C, et al: Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment. J Cell Mol Med 2002;6:570-582.
83.
Mantovani G, Macciò A, Madeddu C, et al: Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy. Oncol Rep 2002;9:887-896.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.